HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services

This article was originally published in The Rose Sheet

Executive Summary

Recent procurement activities show an agency increasingly focused on cosmetics’ safety vis-a-vis microbial threats and, in the case of talc-containing products, asbestos. Meanwhile, FDA seeks a 3D bioprinter to use in organ toxicity studies as an alternative to traditional animal models.


Related Content

Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
Stakeholders Converge On California For Animal-Testing Bill Showdown
FDA Analysis Of Non-Traditionally Preserved Cosmetics Indicates Likely Contamination Source
J&J Hopes To Continue Appellate Streak Following Whopping $4.69bn Talc Verdict
‘Asbestos-Free’ A Relative Term? SAI Testing Expert On Cosmetic Talc Challenges
FDA ‘Actively Investigating’ Asbestos In Cosmetics; Claire’s Rebuts New Allegations
House Bill Seeks Asbestos Warnings On Unverified Kids' Cosmetics With Talc





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts